Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sales of Ethical Drugs Down 1.6% in May: Crecon
July 27, 2009
- REGULATORY NEWS IN BRIEF
July 27, 2009
- NDA for Sitagliptin to Be Reviewed
July 27, 2009
- Points at Issue Proposed by Korosho Regarding NHI Price Maintenance System
July 27, 2009
- DPO Proposes New Pricing Rule for Combination Drugs
July 27, 2009
- Question Raised Again on Need for Exceptional Price Maintenance System
July 27, 2009
- BUSINESS NEWS IN BRIEF
July 27, 2009
- Patients, Doctors Remain Calm Despite EASD Reports on Lantus: sanofi-aventis
July 27, 2009
- Cravit No. 1 on HP Market, No. 2 on GP Market: Rep Track Survey
July 27, 2009
- Merck Serono Aims at Becoming No. 1 in Reproductive Health, Metabolic Oncology
July 27, 2009
- Hisamitsu to Acquire Noven Pharm. to Strengthen US Business Platform
July 27, 2009
- Flat-Sum System to Be Maintained for High-Priced Drugs
July 20, 2009
- Micombi Can Be Differentiated from Other Combination Drugs: Mr Imahori of Astellas
July 20, 2009
- Fuji Keizai Predicts 4% Increase in OTC Anti-Obesity Drugs in 2009
July 20, 2009
- Higher Dosage Approved for Cravit: Daiichi Sankyo
July 20, 2009
- Sales of Class 1 OTC Drugs Down due to New Marketing System
July 20, 2009
- New Class 1 OTC Drugs Get Off to Flying Start: Taisho
July 20, 2009
- R&D NEWS IN BRIEF
July 20, 2009
- Japan Biotechnology Conference Kicked Off by 20 Biotech Firms
July 20, 2009
- ASCO 2009 Highlight Seminar by the Matson Jack Group
July 20, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…